Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary...

Full description

Bibliographic Details
Main Authors: Satoshi Shinozaki, Hiroaki Nomoto, Yoshie Kondo, Hirotsugu Sakamoto, Yoshikazu Hayashi, Hironori Yamamoto, Alan Kawarai Lefor, Hiroyuki Osawa
Format: Article
Language:English
Published: Wiley 2016-05-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X16300304
id doaj-c340fa839a0549999c71958ad5c47e64
record_format Article
spelling doaj-c340fa839a0549999c71958ad5c47e642020-11-25T01:13:23ZengWileyKaohsiung Journal of Medical Sciences1607-551X2016-05-0132525526010.1016/j.kjms.2016.04.009Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pyloriSatoshi Shinozaki0Hiroaki Nomoto1Yoshie Kondo2Hirotsugu Sakamoto3Yoshikazu Hayashi4Hironori Yamamoto5Alan Kawarai Lefor6Hiroyuki Osawa7Shinozaki Medical Clinic, Utsunomiya, JapanDepartment of Gastroenterology, Haga Red Cross Hospital, Moka, JapanDepartment of Gastroenterology, Haga Red Cross Hospital, Moka, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanDepartment of Surgery, Jichi Medical University, Shimotsuke, JapanDivision of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, JapanAlternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73% (419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01) and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe gastric atrophy (p < 0.01). The VAC group had a significantly higher H. pylori eradication rate than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy.http://www.sciencedirect.com/science/article/pii/S1607551X16300304AntibioticsGastric acidHelicobacter pyloriProton pump inhibitorsTreatment outcome
collection DOAJ
language English
format Article
sources DOAJ
author Satoshi Shinozaki
Hiroaki Nomoto
Yoshie Kondo
Hirotsugu Sakamoto
Yoshikazu Hayashi
Hironori Yamamoto
Alan Kawarai Lefor
Hiroyuki Osawa
spellingShingle Satoshi Shinozaki
Hiroaki Nomoto
Yoshie Kondo
Hirotsugu Sakamoto
Yoshikazu Hayashi
Hironori Yamamoto
Alan Kawarai Lefor
Hiroyuki Osawa
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
Kaohsiung Journal of Medical Sciences
Antibiotics
Gastric acid
Helicobacter pylori
Proton pump inhibitors
Treatment outcome
author_facet Satoshi Shinozaki
Hiroaki Nomoto
Yoshie Kondo
Hirotsugu Sakamoto
Yoshikazu Hayashi
Hironori Yamamoto
Alan Kawarai Lefor
Hiroyuki Osawa
author_sort Satoshi Shinozaki
title Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
title_short Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
title_full Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
title_fullStr Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
title_full_unstemmed Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
title_sort comparison of vonoprazan and proton pump inhibitors for eradication of helicobacter pylori
publisher Wiley
series Kaohsiung Journal of Medical Sciences
issn 1607-551X
publishDate 2016-05-01
description Alternative eradication therapies for Helicobacter pylori infection are needed because of an increasing failure rate over the past decade. The aim of this study was to determine if vonoprazan, a new potassium-competitive acid blocker, showed superiority to existing proton pump inhibitors for primary eradication of H. pylori in routine clinical practice. Data for 573 patients who underwent primary H. pylori eradication therapy were retrospectively reviewed. Regimens included clarithromycin 200 mg, amoxicillin 750 mg, and an acid-suppressing drug [lansoprazole 30 mg (LAC), rabeprazole 10 mg (RAC), esomeprazole 20 mg (EAC), or vonoprazan 20 mg (VAC)] twice daily for 1 week. Eradication was successful in 73% (419/573) of patients using intention-to-treat (ITT) analysis and 76% (419/549) of patients in per-protocol (PP) analysis. The VAC group had a significantly superior eradication rate compared with the LAC and RAC groups in ITT (VAC 83%, LAC 66% and RAC 67%, p < 0.01) and PP analysis (VAC 85%, LAC 69% and RAC 70%, p < 0.01), and had a similarly high eradication rate to the EAC group (83% in ITT and 87% in PP). Although the eradication rate in the VAC and EAC groups was not significantly higher than in the LAC and RAC groups in patients with mild gastric atrophy with both ITT and PP analyses, it was significantly higher in patients with severe gastric atrophy (p < 0.01). The VAC group had a significantly higher H. pylori eradication rate than the LAC and RAC groups, and a > 80% eradication rate regardless of the degree of atrophy.
topic Antibiotics
Gastric acid
Helicobacter pylori
Proton pump inhibitors
Treatment outcome
url http://www.sciencedirect.com/science/article/pii/S1607551X16300304
work_keys_str_mv AT satoshishinozaki comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT hiroakinomoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT yoshiekondo comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT hirotsugusakamoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT yoshikazuhayashi comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT hironoriyamamoto comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT alankawarailefor comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
AT hiroyukiosawa comparisonofvonoprazanandprotonpumpinhibitorsforeradicationofhelicobacterpylori
_version_ 1725162722402762752